Q-omics provides the consensus-scored BMS1P16 profile across patient tissues and cancer cell-line models. BMS1P16 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, BMS1P16 is differentially expressed in 5, with the highest sampling consensus in LIHC. Additionally, BMS1P16 RNA expression shows 6,433 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CESC, LIHC, and STAD as cancer lineages where BMS1P16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BMS1P16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BMS1P16 survival associations across molecular data types. BMS1P16 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BMS1P16 RNA expression–survival associations across cancer types. High BMS1P16 expression shows unfavorable associations in CESC and LUSC, but favorable associations in ACC, SKCM, UCS and BLCA. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for BMS1P16 RNA expression.
This table summarizes BMS1P16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for BMS1P16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BMS1P16 shows higher tumor expression in LIHC, READ, LUSC, BLCA and KICH. The LIHC box plot shows higher BMS1P16 RNA expression in tumor versus normal tissue (log2 FC = +0.080, t-test p = .009).
This table shows molecular features associated with BMS1P16 in patient tissues and cancer cell lines. In patient samples, BMS1P16 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
